# OnCo record nct06646055 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06646055/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06646055", "NCT06646055" ;
  schema:name "AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer"@en ;
  schema:description "A phase 1/2 trial of Ivonescimab, Cadonilimab, Paclitaxel / nab-paclitaxel in pancreatic ductal adenocarcinoma, run by Akeso, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06646055/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06646055> ;
  onco:status "active" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "1/2" ;
  schema:startDate "2025-01-21" ;
  onco:cancers <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/metastatic-pdac/> ;
  onco:technologies <https://onco.cc/technologies/bispecific-antibody/>, <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/ivonescimab/>, <https://onco.cc/drugs/cadonilimab/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/drugs/gemcitabine/> ;
  onco:companies <https://onco.cc/companies/akeso/> .